Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

BACKGROUND: The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (ER)+, lymph node-negative breast cancer. METHODS: In this study, we utilized da...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaafsma, Evelien, Zhang, Baoyi, Schaafsma, Merit, Tong, Chun-Yip, Zhang, Lanjing, Cheng, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285794/
https://www.ncbi.nlm.nih.gov/pubmed/34274003
http://dx.doi.org/10.1186/s13058-021-01453-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285794/
https://www.ncbi.nlm.nih.gov/pubmed/34274003
http://dx.doi.org/10.1186/s13058-021-01453-4

Ejemplares similares